Elevation of Isoprostanes in Polycystic Ovary Syndrome and Its Relationship with Cardiovascular Risk Factors

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2018 Apr 25

PMID 29687417

Citations 3

Authors

M Calzada

N Lopez

J A Noguera

J Mendiola

A M Torres

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the plasma level of 8-isoprostanes in women with polycystic ovary syndrome. To also investigate whether there is a relationship between 8-isoprostanes and several cardiovascular risk factors.

Methods: A total of 125 women with polycystic ovary syndrome and 169 healthy women were enrolled in this case-control study. 8-Isoprostanes and different parameters were measured in all subjects. Patients were evaluated for the presence of polycystic ovary syndrome according to the Rotterdam Consensus Conference criteria.

Results: 8-Isoprostanes levels were significantly higher in patients with polycystic ovary syndrome (138.4 ± 104.1 pg/mL) compared with control group (68.6 ± 34.3 pg/mL) (p < 0.001). The mean of triglycerides, lipid accumulation product, C-reactive protein, homocysteine, insulin, and homeostatic model assessment for insulin resistance were significantly higher in polycystic ovary syndrome patients with high 8-isoprostanes than those with normal 8-isoprostanes (p < 0.05). The Pearson correlation analyses showed that 8-isoprostanes levels in polycystic ovary syndrome group had a positive correlation with waist circumference, triglycerides, low-density lipoprotein cholesterol, apolipoprotein B, homocysteine, insulin, homeostatic model assessment for insulin resistance.

Conclusions: Patients with polycystic ovary syndrome have higher 8-isoprostanes levels and it is associated with several cardiovascular risk factors.

Citing Articles

Homocysteine, vitamin B12, and folate circulating levels in women with and without polycystic ovary syndrome: A systematic review and meta-analysis.

Ulloque-Badaracco J, Al-Kassab-Cordova A, Hernandez-Bustamante E, Alarcon-Braga E, Cabrera-Guzman J, Horruitiner-Mendoza A Womens Health (Lond). 2024; 20:17455057241279039.

PMID: 39320480 PMC: 11437568. DOI: 10.1177/17455057241279039.

Biomarkers in Polycystic Ovary Syndrome.

Huffman A, Rezq S, Basnet J, Romero D Curr Opin Physiol. 2023; 36.

PMID: 37842179 PMC: 10569288. DOI: 10.1016/j.cophys.2023.100717.

Cardiovascular Risk According to Body Mass Index in Women of Reproductive Age With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Zhuang C, Luo X, Wang W, Sun R, Qi M, Yu J Front Cardiovasc Med. 2022; 9:822079.

PMID: 35252398 PMC: 8893173. DOI: 10.3389/fcvm.2022.822079.

References

Ueland P, Refsum H, Beresford S, Vollset S . The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000; 72(2):324-32. DOI: 10.1093/ajcn/72.2.324. View

Paradisi G, Steinberg H, Hempfling A, Cronin J, Hook G, SHEPARD M . Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001; 103(10):1410-5. DOI: 10.1161/01.cir.103.10.1410. View

Knekt P, Alfthan G, Aromaa A, Heliovaara M, Marniemi J, Rissanen H . Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med. 2001; 249(5):461-5. DOI: 10.1046/j.1365-2796.2001.00830.x. View

Rosenfield R . Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol. 2001; 45(3 Suppl):S95-104. DOI: 10.1067/mjd.2001.117430. View

Sabuncu T, Vural H, Harma M . Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001; 34(5):407-13. DOI: 10.1016/s0009-9120(01)00245-4. View

Cracowski J, Durand T, Bessard G . Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci. 2002; 23(8):360-6. DOI: 10.1016/s0165-6147(02)02053-9. View

Christian R, Dumesic D, Behrenbeck T, Oberg A, Sheedy 2nd P, Fitzpatrick L . Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88(6):2562-8. DOI: 10.1210/jc.2003-030334. View

Fenkci V, Fenkci S, Yilmazer M, Serteser M . Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003; 80(1):123-7. DOI: 10.1016/s0015-0282(03)00571-5. View

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

10.

Belli S, Graffigna M, Oneto A, Otero P, Schurman L, Levalle O . Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril. 2004; 81(3):624-9. DOI: 10.1016/j.fertnstert.2003.08.024. View

11.

Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O . Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004; 89(5):2160-5. DOI: 10.1210/jc.2003-031096. View

12.

Tyagi N, Sedoris K, Steed M, Ovechkin A, Moshal K, Tyagi S . Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol. 2005; 289(6):H2649-56. DOI: 10.1152/ajpheart.00548.2005. View

13.

Kahn H . The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005; 5:26. PMC: 1236917. DOI: 10.1186/1471-2261-5-26. View

14.

Boudreaux M, Talbott E, Kip K, Brooks M, Witchel S . Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep. 2006; 6(1):77-83. DOI: 10.1007/s11892-006-0056-1. View

15.

Carmina E, Orio F, Palomba S, Longo R, Cascella T, Colao A . Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med. 2006; 119(4):356.e1-6. DOI: 10.1016/j.amjmed.2005.10.059. View

16.

Badawy A, State O, El Gawad S, El Aziz O . Plasma homocysteine and polycystic ovary syndrome: the missed link. Eur J Obstet Gynecol Reprod Biol. 2006; 131(1):68-72. DOI: 10.1016/j.ejogrb.2006.10.015. View

17.

Norman R, Dewailly D, Legro R, Hickey T . Polycystic ovary syndrome. Lancet. 2007; 370(9588):685-97. DOI: 10.1016/S0140-6736(07)61345-2. View

18.

Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale H . Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod. 2007; 22(12):3197-203. DOI: 10.1093/humrep/dem324. View

19.

Cascella T, Palomba S, de Sio I, Manguso F, Giallauria F, De Simone B . Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. 2007; 23(1):153-9. DOI: 10.1093/humrep/dem356. View

20.

Basu S . F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal. 2008; 10(8):1405-34. DOI: 10.1089/ars.2007.1956. View